Is IMVT or LNTH more profitable?

LNTH runs the higher net margin — IMVT at -7585.86% versus LNTH at 17.69%.

How have IMVT and LNTH total returns compared?

Over the past 5 years, IMVT delivered 29.93% and LNTH delivered 31.73% annualized total return. Past performance doesn't predict future results.

Immunovant, Inc. (IMVT) vs Lantheus Holdings, Inc. (LNTH)

A side-by-side comparison of Immunovant, Inc. and Lantheus Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

IMVT

Immunovant, Inc.

$6.49B

$31.44HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT

LNTH

Lantheus Holdings, Inc.

$6.51B

$99.94HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT

Total return — IMVT vs LNTH

growth of $100 · dividends reinvested · last 7y

IMVT +234.2% (+18.8%/yr)LNTH +256.0% (+19.9%/yr)LNTH compounded faster over this window

IMVT LNTH

IMVT vs LNTH: by the numbers

•LNTH is the larger company ($6.51B vs $6.49B market cap).
•LNTH is profitable (17.69% net margin) while IMVT runs a net loss (-7585.86%).

Metrics side by side

Valuation

Metric	IMVT	LNTH
P/E ratio	N/A	24.14
Forward P/E	N/A	18.46
P/S ratio	914.74	4.18
P/B ratio	8.83	4.96
EV / EBITDA	N/A	16.98
FCF yield	N/A	5.96%

Profitability

Metric	IMVT	LNTH
Gross margin	0.00%	60.14%
Operating margin	0.00%	19.43%
Net margin	-7585.86%	17.69%
ROE	-73.19%	20.99%
ROIC	-76.00%	11.03%

Growth (annualized)

Metric	IMVT	LNTH
Revenue CAGR (5Y)	N/A	32.84%
FCF CAGR (5Y)	N/A	59.88%
Total return CAGR (5Y)	29.93%	31.73%

Frequently asked

Is IMVT or LNTH more profitable?: LNTH runs the higher net margin — IMVT at -7585.86% versus LNTH at 17.69%.
How have IMVT and LNTH total returns compared?: Over the past 5 years, IMVT delivered 29.93% and LNTH delivered 31.73% annualized total return. Past performance doesn't predict future results.

Go deeper

Full IMVT analysis Full LNTH analysis Interactive comparison tool

Dig into the metrics

Lantheus P/E ratio Immunovant ROE Lantheus ROE Immunovant operating margin Lantheus operating margin Immunovant revenue growth Lantheus revenue growth Immunovant free cash flow Lantheus free cash flow

Immunovant & Lantheus appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.